# US 2026/0062712 A1 · Optimized lentiviral transfer vectors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062712 A1
- Document ID: US20260062712A1
- Status: Published application
- Kind: A1
- Application number: 19/078,459
- Filed: 2025-03-13
- Published: 2026-03-05
- Earliest claimed: 2015-11-23
- Assignees: Novartis AG; The Trustees of the University of Pennsylvania
- Applicants: Novartis AG; The Trustees of the University of Pennsylvania
- Inventors: Vladimir SLEPUSHKIN; Dmitriy LUKASHEV
- Web page: https://patentgrep.com/patent/US20260062712A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

## Claims

### Claim 1

A lentiviral transfer vector comprising a heterologous nucleic acid sequence and being characterized by at least two of the following features:
(a) comprising a cytomegalovirus (CMV) promoter,
(b) comprising a polynucleotide encoding at least a portion of a gag protein that comprises a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA relative to wild-type INS1,
(c) not comprising a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag, and
(d) not comprising an SV40 origin of replication and/or an f1 origin of replication.

### Claim 2 (depends on 1)

The lentiviral transfer vector of claim 1, characterized by at least three of features (a)-(d).

### Claim 3 (depends on 1)

The lentiviral transfer vector of claim 1, characterized by all of features (a)-(d).

### Claim 4 (depends on 1)

The lentiviral transfer vector of claim 1, comprising a polynucleotide encoding a 150-250 (e.g., 168) nucleotide portion of a gag protein that (i) comprises a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA relative to wild-type INS1, (ii) contains two nucleotide insertion that results in frame shift and premature termination, and/or (iii) does not comprise INS2, INS3, and INS4 inhibitory sequences.

### Claim 5 (depends on 1)

The lentiviral transfer vector of claim 1, further comprising one or more elements selected from the group consisting of a packaging signal (psi), a partial gag sequence adjacent to or partially overlapping with psi, a rev-response element, a partial env sequence, and a cPPT sequence from pol, the sequences of which optionally originate from HIV-1 isolate NL4-3 or SF3.

### Claim 6 (depends on 5)

The lentiviral transfer vector of claim 5, wherein the cPPT sequence comprises about 150-250 (e.g., 178-181) nucleotides and comprises splice acceptor SA1 sequence.

### Claim 7 (depends on 1)

The lentiviral transfer vector of claim 1, further comprising one or more restriction sites positioned between elements of said vector.

### Claim 8 (depends on 1)

The lentiviral transfer vector of claim 1, further comprising a post-transcriptional regulatory element (PRE).

### Claim 9 (depends on 8)

The lentiviral transfer vector of claim 8, wherein said PRE is a woodchuck hepatitis virus PRE (WPRE).

### Claim 10 (depends on 9)

The lentiviral transfer vector of claim 9, wherein said WPRE comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 78.

### Claim 11 (depends on 8)

The lentiviral transfer vector of claim 8, wherein said PRE is a hepatitis B virus isolate bba6 PRE (HPRE).

### Claim 12 (depends on 11)

The lentiviral transfer vector of claim 11, wherein said HPRE comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 79, and optionally wherein said HPRE comprises an inactivating mutation in an X protein-encoding sequence.

### Claim 13 (depends on 1)

The lentiviral transfer vector of claim 1, further comprising an EF1a promoter, optionally wherein said EF1a promoter comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 71, and optionally is full length and comprises intact splice donor and splice acceptor sequences (SEQ ID NOs:72 and 73, respectively) (SEQ ID NO:95).

### Claim 14 (depends on 1)

The lentiviral transfer vector of claim 1, wherein the lentiviral components of said lentiviral transfer vector originate from HIV-1.

### Claim 15 (depends on 1)

The lentiviral transfer vector of claim 1, wherein said heterologous nucleic acid sequence is downstream of a Kozak sequence.

### Claim 16 (depends on 1)

The lentiviral transfer vector of claim 1, wherein the sequence encoding said at least a portion of said gag protein has less than 90% sequence identity to a corresponding region of gag protein encoded by pMDLgpRRE packaging plasmid.

### Claim 17 (depends on 1)

The lentiviral transfer vector of claim 1, wherein said lentiviral transfer vector comprises:
(i) a CMV promoter comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 52,
(ii) an LTR R region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 53,
(iii) an LTR U5 region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 54,
(iv) a primer binding site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 55,
(v) a packaging signal comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 56,
(vi) a major splice donor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 57, which is within said packaging signal,
(vii) a partial gag sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:58,
(viii) a partial env sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:60,
(ix) a Rev-response element comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 62,
(x) a partial env sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:64,
(xi) a splice acceptor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 65, which is within said partial env sequence of part (x),
(xii) a central polypurine tract comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 67, 92, or 93,
(xiii) a splice acceptor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 68 or 94, which is within said central polypurine tract,
(xiv) an EF1alpha promoter having at least 95% sequence identity to SEQ ID NO:71 or 95,
(xv) a constitutive splice donor (CD) site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 72, which is within said EF1alpha promoter,
(xvi) a constitutive splice acceptor (CA) site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 73, which is within said EF1alpha promoter,
(xvii) a polynucleotide encoding an EGFP comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 76 and/or a transgene sequence,
(xviii) a PRE sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 78 or 79,
(xix) a partial nef sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:83,
(xx) a dU3 sequence comprising a nucleic acid sequencing having at least 95% sequence identity to SEQ ID NO:84,
(xxi) an LTR R region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 85, and
(xxii) an LTR U5 region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 86.

### Claim at position 18

18-35. (canceled)

### Claim 36 (depends on 1)

A host cell comprising the lentiviral transfer vector of claim 1.

### Claim at position 20

37-38. (canceled)

### Claim 39 (depends on 1)

A composition comprising a lentiviral transfer vector of claim 1 and one or more packaging vectors.

### Claim 40 (depends on 1)

A method of producing a lentivirus capable of expressing a heterologous nucleic acid sequence, said method comprising:
(a) introducing into a cell:
(i) the lentiviral transfer vector of claim 1, and
(ii) one or more lentiviral packaging vectors; and
(b) expressing viral proteins encoded by said lentiviral transfer vector and/or said packaging vector in said cell, thereby producing a lentivirus comprising the heterologous nucleic acid sequence of said lentiviral transfer vector.

### Claim 41

(canceled)
